iTeos Therapeutics’ (ITOS) “Outperform” Rating Reaffirmed at Wedbush

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a report released on Tuesday,RTT News reports. They presently have a $25.00 price objective on the stock. Wedbush’s price objective points to a potential upside of 172.03% from the company’s current price.

A number of other research analysts also recently weighed in on the company. JPMorgan Chase & Co. decreased their price target on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a research report on Monday, September 16th. Finally, Wells Fargo & Company began coverage on shares of iTeos Therapeutics in a research report on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 price objective for the company.

iTeos Therapeutics Trading Down 2.0 %

Shares of NASDAQ ITOS traded down $0.19 during mid-day trading on Tuesday, hitting $9.19. The company had a trading volume of 370,506 shares, compared to its average volume of 440,045. The firm has a 50-day simple moving average of $10.84 and a two-hundred day simple moving average of $14.07. The company has a market capitalization of $335.62 million, a PE ratio of -3.06 and a beta of 1.39. iTeos Therapeutics has a one year low of $8.41 and a one year high of $18.75.

Institutional Investors Weigh In On iTeos Therapeutics

A number of institutional investors have recently made changes to their positions in ITOS. Candriam S.C.A. bought a new position in iTeos Therapeutics in the 2nd quarter valued at $7,558,000. Acadian Asset Management LLC bought a new stake in iTeos Therapeutics during the first quarter valued at approximately $3,337,000. Clearline Capital LP bought a new stake in shares of iTeos Therapeutics during the 2nd quarter worth $2,328,000. Kennedy Capital Management LLC purchased a new position in shares of iTeos Therapeutics in the 1st quarter worth about $1,988,000. Finally, Algert Global LLC grew its position in iTeos Therapeutics by 92.0% during the third quarter. Algert Global LLC now owns 256,139 shares of the company’s stock valued at $2,615,000 after acquiring an additional 122,730 shares during the last quarter. Institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.